13045_2018_577_MOESM4_ESM.zip (1.03 MB)
Additional file 4: of Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer
dataset
posted on 2018-02-23, 05:00 authored by Bowen Liu, Tianjiao Wang, Huawei Wang, Lu Zhang, Feifei Xu, Runping Fang, Leilei Li, Xiaoli Cai, Yue Wu, Weiying Zhang, Lihong YeFigure S1. HBXIP contributes to TAM resistance in breast cancer. Figure S2. HBXIP induces TAM resistance by increasing the protein level of HOXB13. Figure S3. HBXIP enhances acetylation of HOXB13 at K277 site via acetylase p300. Figure S4. HBXIP-enhanced acetylation of HOXB13 stabilizes HOXB13 in the facilitation of TAM resistance. Figure S5. HBXIP co-activates HOXB13 to stimulate IL-6 transcription. Figure S6. ASA suppresses HBXIP/HOXB13 axis by reducing HBXIP expression. Figure S7. ASA-inhibited HBXIP/HOXB13 axis contributes to the reversal of TAM resistance. Figure S8. Diagram of working model. (ZIP 1058 kb)
